Site-Selective Nickel-Catalyzed Hydrogen Isotope Exchange in <i>N</i>-Heterocycles and Its Application to the Tritiation of Pharmaceuticals
作者:Haifeng Yang、Cayetana Zarate、W. Neil Palmer、Nelo Rivera、David Hesk、Paul J. Chirik
DOI:10.1021/acscatal.8b03717
日期:2018.11.2
advantages over existing methods, including: (i) high HIE activity at low D2 or T2 pressure; (ii) tolerance of functional groups, including aryl chlorides, alcohols, secondary amides, and sulfones; (iii) activity with nitrogen-rich molecules such as the chemotherapeutic imatinib; and (iv) the ability to promote HIE in sterically hindered positions generally inaccessible with other transition metal catalysts
描述了一种镍催化的氮杂芳烃中C(sp 2)-H键的位点选择性氢同位素交换(HIE)的镍催化方法,并将其应用于药物的ti代反应。α-亚胺镍氢化物配合物[(的iPr DI)的Ni(μ 2 -H)] 2(的iPr DI = Ñ,Ñ使用时' -双(2,6-二异丙基苯基)-2,3- butanediimine)介导有效的HIE作为单一组分的预催化剂或由易于获得的和空气稳定的金属和配体前体(iPr DI,[(NEt 3)Ni(OPiv)2 ] 2(Piv =新戊酰)和(EtO)3SiH)。与现有方法相比,镍催化剂具有明显的优势,包括:(i)在低D 2或T 2下的高HIE活性压力; (ii)对官能团的耐受性,包括芳基氯,醇,仲酰胺和砜;(iii)具有富氮分子如化学治疗的伊马替尼的活性;(iv)在其他受阻金属催化剂通常无法达到的空间位阻位置促进HIE的能力。代表性活性药物成分的tri化活性超出了药物吸收,分布,代谢和排泄研究(1